In the phase 2 TBCRC 022 study, neratinib was effective against refractory, HER2-positive breast cancer BM, with CNS ORR of 49% in the lapatinib-naïve cohort and 33% in the lapatinib-pretreated cohort (45). The gene discussed is ERBB2; the disease is breast carcinoma.